Original Article
Author Details :
Volume : 10, Issue : 2, Year : 2024
Article Page : 159-164
https://doi.org/10.18231/j.ijced.2024.029
Abstract
Background: Acne is a common skin condition affecting adolescents and young adults, characterized by the blockage of sebaceous glands along with bacterial colonization of the follicular duct and inflammation. Collagen and tissue damage secondary to acne inflammation brings about severe skin texture changes, including scarring. Timely treatment initiation is crucial to prevent acne progression to scarring. Topical retinoids, topical oral antimicrobials, or a combination of both are recommended as the first-line therapy for acne. The objective of the present survey was to assess the role of 0.3% adapalene/2.5% benzoyl peroxide (BPO) combination in those with mild-moderate acne.
Objective: The objective of the present survey was to assess the role of 0.3% adapalene/2.5% BPO combination in those with mild-moderate acne.
Materials and Methods : A total of 438 healthcare professionals (dermatologists and cosmetologists) participated in the survey, through which their patients’ experiences with the product were recorded.
Results : A significant proportion of the patient population (31%) experienced improvement just after 2 weeks of treatment with the combination. Most patients (84%) also found it easy to include the product in their skincare regime. Most healthcare professionals and patients (>80%) rated the effectiveness and tolerability of the intervention as ‘good’ to ‘excellent’.
Conclusion : The survey confirms the 0.3% adapalene/2.5% BPO combination as an efficacious, easy-to-use topical treatment option for moderate to severe acne with the potential to impact acne scars, in line with findings from other studies examining the effect of this combination.
Keywords: Acne, Scarring, Retinoid, Antimicrobial, Combination therapy
How to cite : Walia P, Agarwal M, Sen D, Jadhwar S, A survey assessing the role of a fixed-dose combination of 0.3% adapalene with 2.5% benzoyl peroxide in acne vulgaris. IP Indian J Clin Exp Dermatol 2024;10(2):159-164
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Received : 15-03-2024
Accepted : 04-04-2024
Viewed: 676
PDF Downloaded: 209